Identify and address inequities in cancer care and outcomes
“
Without this data it is impossible to truly know...are we delivering equitable care, equitable outcomes across the regional, remote, very remote, metro populations, your Aboriginal, non-Aboriginal populations, your cultural, linguistic, diverse populations, often forgotten group people living with disabilities, are they receiving equitable care as well? It’s absolutely critical for that. [I]t’s time to make this equitable. It shouldn’t matter where you’re diagnosed or where you live. You should have access to the best treatment and the best care, and that includes some of this data that drives those innovations. [S]tage of cancer at diagnosis is the most important predictor of survival, and if you can’t get that, then, you can’t possibly tell the story of inequity in our health system. It’s just such a critical data field to look at priority populations, to be able to see whether the cancer plan is actually working, to assess screening programmes. It just is critically important. I want [data captured] for everyone... from a clinical trials perspective, we can have greater equity and access to clinical trials if we know where these people are.
Enable more efficient and targeted budget planning, allocation and investment
“
The benefit to [governments] is that they have a much better idea of how to control their spend, and they have a better idea of how to understand and explain to the taxpayer the benefit of that spend in early disease and metastatic across the whole cost of the care of that patient, and to target those areas that are inequitable.
November 2023
33
Made with FlippingBook - professional solution for displaying marketing and sales documents online